Valvular & structural heart disease
Long-Term Outcomes After Edge-to-Edge Repair of Secondary Mitral Regurgitation: 5-Year Results From the EuroSMR Registry
Authors' conclusion
This extensive multicenter registry underscores the long-term efficacy of M-TEER in real-world clinical practice and identifies predictors for long-term survival.
Study context
- Population
- Patients with significant secondary mitral regurgitation (MR) undergoing M-TEER (mean age 73.8 years, mean EuroSCORE II 6.9%, 86.6% NYHA class ≥III)
- Participants
- 1,628 patients
- Outcome
- Long-term MR reduction, functional outcomes, survival and predictors of all-cause mortality
- Follow-up
- 5 years
Methodological detailsmulticentre, real-world registry (EuroSMR)
- Multicentre
- Real-world registry (EuroSMR)
Main finding
As reported in the abstract
Five-year survival after M-TEER
Five-year survival
35.0%
Observational data: associations, not effects.
Further findings
5-year survival by residual MR grade
- Residual MR ≤1+
- 38.6%
- Residual MR 2+
- 30.5%
- Residual MR ≥3+
- 22.6%
- P < 0.001
Independent predictors of 5-year all-cause mortality
- Age, renal function, residual MR, NYHA class, LVEF and COAPT trial eligibility
- P < 0.01 for all
Original publication
Long-Term Outcomes After Edge-to-Edge Repair of Secondary Mitral Regurgitation: 5-Year Results From the EuroSMR Registry. JACC Cardiovasc Interv. Published 11 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →